Cue Biopharma Inc (CUE) Stock Price, Quote & News

Company Profile

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 949 2680

Website: www.cuebiopharma.com

Address:

40 Guest Street, Boston, United States

GordoHLYK13 Apr. 8 at 12:19 PM

$CUE https://www.cuebiopharma.com/news/ CUE just unlocked a $7.5M milestone from a major partner — that’s cash coming before any clinic readouts, and it shows big-pharma confidence in their B-cell tech. With fresh catalysts on the calendar and real validation from collaborators, this isn’t just a pump — it’s fundamental progress. If smart money starts sniffing that out, we could see follow-through on volume and price as the market reprices the story. 💥

0 · Reply

GordoHLYK13 Apr. 8 at 12:11 PM

$CUE showed that quick pop to $0.21—nice move. Now let’s see how it holds once the market opens and bigger players start recognizing the potential of their cancer tech. Yesterday was mostly day traders chasing momentum; if it continues higher, that’s when you know smarter money is stepping in.

0 · Reply

Bakhm Apr. 8 at 12:11 PM

$CUE $QNCX

0 · Reply

Bakhm Apr. 8 at 12:08 PM

$CUE nice news

0 · Reply

GordoHLYK13 Apr. 8 at 11:37 AM

$CUE Clean setup, tight risk, and a clear catalyst window — that’s how breakouts are built. If the stock holds that $0.17–$0.19 range, it’s not weakness, it’s coiling for a move. Let the fear of dilution fade while the chart builds strength. Friday power hour could be the ignition — positioning early is where the edge is. Stay disciplined, the move rewards patience. 🚀 The Boehringer milestone isn’t just a headline — it’s real non-dilutive cash hitting the balance sheet, validating Cue’s science and partnership. Couple that with R&D Day visibility on CUE-401 and proactive leadership moves, and you’ve got tangible fundamentals behind the technical setup. Friday’s action could be the market starting to price in that de-risking. 🚀 Next Monday is the shareholder meeting where the reverse split is likely to be approved, but I’m holding through Friday—I’m not leaving anything on the table.

0 · Reply

VapourWave Apr. 8 at 11:20 AM

Breakout starting on ticker CYCU ✅ News yesterday and plus got a $7 dollar buy rating! -Cybersecurity is becoming mandatory infrastructure and CYCU is right in the middle of it. -While the world is dealing with rising cyber threats, this company is building backlog and contracts. Add in short pressure and you’ve got serious squeeze potential if volume steps in. With markets heating up CYCU can be a big runner, Only 2M float! $LXEH $MEHA $CUPR $CUE //..12

0 · Reply

AlphaBull_10M Apr. 8 at 10:58 AM

$WULF $TPET $CUE $SES Jesus, how many times you have to post the same thing. I'll mute you now.

0 · Reply

_TannerTechnicals Apr. 8 at 10:57 AM

$WULF $TPET $CUE $SES copy

0 · Reply

Gainermaxim Apr. 8 at 9:39 AM

$CUE Need some volume and this gonna rockkkkkk

0 · Reply

_TannerGetsit Apr. 8 at 9:25 AM

$SES $CUE $POET $WULF respect

0 · Reply

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

Mar 27, 2026, 4:05 PM EDT - 11 days ago

Cue Biopharma Announces CEO Transition

Mar 26, 2026, 8:00 AM EDT - 13 days ago

Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

Mar 16, 2026, 4:05 PM EDT - 22 days ago

Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Mar 9, 2026, 8:00 AM EDT - 4 weeks ago

Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026

Feb 17, 2026, 8:00 AM EST - 7 weeks ago

Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases

Feb 12, 2026, 8:00 AM EST - 7 weeks ago

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer

Dec 19, 2025, 8:00 AM EST - 3 months ago

Cue Biopharma Announces Pricing of $10 Million Public Offering

Dec 18, 2025, 4:02 PM EST - 3 months ago

Cue Biopharma Announces Proposed Public Offering

Nov 12, 2025, 4:05 PM EST - 5 months ago

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 8:00 AM EST - 5 months ago

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

Sep 29, 2025, 9:00 AM EDT - 6 months ago

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

Aug 21, 2025, 8:00 AM EDT - 8 months ago

Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

Aug 13, 2025, 8:00 AM EDT - 8 months ago

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

Aug 12, 2025, 4:05 PM EDT - 8 months ago

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 16, 2025, 8:00 AM EDT - 9 months ago

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Jul 1, 2025, 4:05 PM EDT - 10 months ago

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

Jun 24, 2025, 4:48 PM EDT - 10 months ago

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

May 12, 2025, 4:05 PM EDT - 11 months ago

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 8:00 AM EDT - 11 months ago

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

May 5, 2025, 10:00 AM EDT - 1 year ago

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

Apr 15, 2025, 2:00 AM EDT - 1 year ago

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Apr 14, 2025, 10:23 PM EDT - 1 year ago

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Apr 14, 2025, 5:02 PM EDT - 1 year ago

Cue Biopharma to Host Business Update Call and Webcast

Mar 31, 2025, 4:20 PM EDT - 1 year ago

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Nov 29, 2024, 4:30 PM EST - 1 year ago

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 25, 2024, 8:00 AM EST - 1 year ago

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 4:05 PM EST - 1 year ago

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 8:00 AM EST - 1 year ago

Cue Biopharma Announces Strategic Organizational Transition

Nov 8, 2024, 1:30 PM EST - 1 year ago

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 26, 2024, 11:26 PM EDT - 1 year ago

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Sep 26, 2024, 11:10 PM EDT - 1 year ago

Cue Biopharma Announces Proposed Public Offering

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Aug 19, 2024, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Apr 24, 2024, 10:01 AM EDT - 2 years ago

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2024, 4:05 PM EDT - 2 years ago

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Feb 29, 2024, 10:00 AM EST - 2 years ago

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Nov 22, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Nov 7, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

Sep 27, 2023, 9:05 AM EDT - 2 years ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Aug 9, 2023, 4:10 PM EDT - 2 years ago

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jun 7, 2023, 8:00 AM EDT - 3 years ago

Cue Biopharma to Host Investor Call

Jun 5, 2023, 8:00 AM EDT - 3 years ago

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

May 25, 2023, 5:00 PM EDT - 3 years ago

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 9, 2023, 4:35 PM EDT - 3 years ago

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 8, 2023, 8:00 AM EDT - 3 years ago

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

GordoHLYK13 Apr. 8 at 12:19 PM

0 · Reply

GordoHLYK13 Apr. 8 at 12:11 PM

0 · Reply

Bakhm Apr. 8 at 12:11 PM

$CUE $QNCX

0 · Reply

Bakhm Apr. 8 at 12:08 PM

$CUE nice news

0 · Reply

GordoHLYK13 Apr. 8 at 11:37 AM

0 · Reply

VapourWave Apr. 8 at 11:20 AM

0 · Reply

AlphaBull_10M Apr. 8 at 10:58 AM

$WULF $TPET $CUE $SES Jesus, how many times you have to post the same thing. I'll mute you now.

0 · Reply

_TannerTechnicals Apr. 8 at 10:57 AM

$WULF $TPET $CUE $SES copy

0 · Reply

Gainermaxim Apr. 8 at 9:39 AM

$CUE Need some volume and this gonna rockkkkkk

0 · Reply

_TannerGetsit Apr. 8 at 9:25 AM

$SES $CUE $POET $WULF respect

0 · Reply

Bio_Be_Dirty Apr. 8 at 5:46 AM

$CUE dead , get the coffin

0 · Reply

Ph777trader Apr. 8 at 3:27 AM

$CUE

0 · Reply

TraderJoeee Apr. 8 at 3:05 AM

$CUE and we are back to $0.20 in overnight

2 · Reply

_SupermanTrdez Apr. 8 at 1:36 AM

Keep a close watch on CYCU ✅ News this morning and plus got a $7 dollar buy rating! -Cybersecurity is becoming mandatory infrastructure and CYCU is right in the middle of it. -While the world is dealing with rising cyber threats, this company is building backlog and contracts. Add in short pressure and you’ve got serious squeeze potential if volume steps in. With markets heating up CYCU can be a big runner! $CETX $LNAI $CUE $PLUG //.12

1 · Reply

GordoHLYK13 Apr. 8 at 1:19 AM

$CUE today’s R&D Day presentation highlights a significant shift in momentum. Management shared compelling new data on CUE-401, confirming its potential as a "master switch" for treating autoimmune diseases by restoring immune balance. Beyond the science, the outlook is bolstered by tangible progress: • $7.5M Milestone: Just last week, Boehringer Ingelheim triggered a $7.5 million payment after selecting the first compound for lead optimization in their B cell depletion partnership. • Clinical Path: The company is fully focused on moving CUE-401 into clinical trials by the second half of this year. • Leadership Transition: With Lucinda Warren stepping in as Interim CEO, the focus has pivoted to executing creative deals and reclaiming rights to key assets like CUE-401 to drive shareholder value. The stock has been under pressure, but the pipeline development and recent non-dilutive cash injection provide a much-needed positive catalyst.

0 · Reply

GordoHLYK13 Apr. 7 at 11:37 PM

$CUE CUE-401 is actually high-level science — not fluff. It’s a first-in-class approach combining IL-2 + TGF-β to act like a “master switch,” turning inflammatory T-cells into regulatory T-cells and restoring immune balance — something most autoimmune drugs don’t do (they just suppress symptoms). Today’s presentation basically reinforced 3 key points: • Strong preclinical safety (no major adverse events) • Selective Treg expansion (precision vs broad immunosuppression) • Clear path toward IND / human trials Why Warren matters: Lucinda Warren is a capital allocator + dealmaker, not just a scientist — exactly what a small biotech needs right now. Translation: 👉 More partnerships 👉 More non-dilutive cash (like the $7.5M) 👉 Sharper execution vs prior leadership Bottom line: CUE-401 = high-upside, differentiated mechanism Warren = execution + funding focus That combo is what turns science into shareholder value.

1 · Reply

focafoca99 Apr. 7 at 9:30 PM

$CUE says Boehringer Ingelheim selected the first compound for lead optimization under their collaboration, triggering a $7.5 million milestone expected in May.

0 · Reply

NEWYORKSILVERKING Apr. 7 at 8:46 PM

$CUE When you`re a micro cap biotech and get awarded a milestone payment that`s nearly half the market cap why wouldn`t you put out an actual press release after filing the 8k with the SEC?

0 · Reply

lambo2220 Apr. 7 at 7:54 PM

$CUE

0 · Reply

SirDuncan Apr. 7 at 7:16 PM

$CUE after taking a closer look at the tape action, it is abundantly clear that a large seller used this as an opportunity to unload a massive position. Looks like they wanted out just prior to the reverse split later this month.

1 · Reply

Legends0fWick Apr. 7 at 6:49 PM

Small cap is hot, Massive breakout starting on CYCU 🚨 CYCU with massive cyber security news today. With just 2M float can CYCU be the next parabolic runner? Make sure you have ticker CYCU on watch. Market is looking super hot right now, CYCU can go big!! $MIGI $CUE $IPST $ARTL ..//11

0 · Reply

suavetrader945 Apr. 7 at 6:38 PM

$CUE What’s the move with this one

0 · Reply

Market Cap	17.22M
Revenue (ttm)	27.47M
Net Income (ttm)	-26.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-96.83%
Debt to Equity Ratio	0.00

Volume	75,983,906
Avg Vol	2,871,572
Day's Range	N/A - N/A
Shares Out	97.28M
Stochastic %K	22%
Beta	1.57
Analysts	Strong Sell
Price Target	$3.33